Literature DB >> 21382168

Transforming growth factor-α attenuates hepatic fibrosis: possible involvement of matrix metalloproteinase-1.

Tatsuya Ohyama1, Yuichi Yamazaki, Ken Sato, Norio Horiguchi, Takeshi Ichikawa, Satoru Kakizaki, Hitoshi Takagi, Masatomo Mori.   

Abstract

BACKGROUND: The effect of transforming growth factor (TGF)-α on fibrosis varies between cell types and the role of TGF-α in hepatic fibrosis has not been fully elucidated.
METHODS: We examined the effect of TGF-α on hepatic fibrosis using TGF-α-expressing transgenic mice fed a methionine- and choline-deficient (MCD) diet and human hepatic stellate cells (HSCs) line LX-2, rat and human primary HSCs.
RESULTS: Although the expression levels of the tissue inhibitor of metalloproteinases-1 and α1(I) collagen mRNA were unchanged, feeding the TGF-α transgenic mice the MCD diet resulted in greater expression of the murine functional analogue of matrix metalloproteinase-1 (MMP-1), MMP-13 mRNA and protein and attenuated hepatic fibrosis compared with wild-type mice. TGF-α overexpression did not affect the extent of the steatosis, oxidative stress and hepatic inflammation in the MCD diet-fed mice. The effect of TGF-α on the fibrogenic and anti-fibrogenic gene expressions varied between cell types in vitro. TGF-α increased MMP-1 mRNA expressions that were completely blocked by gefitinib in LX-2 cells. The extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase and p38 pathways were involved in MMP-1 mRNA expression in LX-2 cells. Although TGF-α increased the phosphorylation of p38, the p38 inhibitor activated the RAS-ERK pathway and increased TGF-α-induced MMP-1 mRNA expression, which suggested that there may be a crosstalk between the RAS-ERK and the p38 pathways in LX-2 cells.
CONCLUSIONS: The TGF-α may attenuate hepatic fibrosis in part because of upregulation of the expression of MMP-1. The balance between fibrogenic and anti-fibrogenic gene expression and between the activity of the RAS-ERK and the p38 pathways may be crucial for the fibrotic process.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382168     DOI: 10.1111/j.1478-3231.2011.02475.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models.

Authors:  Seong Hee Kang; Hyung Joon Yim; Ji-Won Hwang; Mi-Jung Kim; Young-Sun Lee; Young Kul Jung; Hyungshin Yim; Baek-Hui Kim; Hae-Chul Park; Yeon Seok Seo; Ji Hoon Kim; Jong Eun Yeon; Soon Ho Um; Kwan Soo Byun
Journal:  Korean J Intern Med       Date:  2022-06-08       Impact factor: 3.165

Review 2.  EGFR Signaling in Liver Diseases.

Authors:  Karin Komposch; Maria Sibilia
Journal:  Int J Mol Sci       Date:  2015-12-29       Impact factor: 5.923

3.  The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.

Authors:  Sheila M Keating; Jennifer L Dodge; Philip J Norris; John Heitman; Stephen J Gange; Audrey L French; Marshall J Glesby; Brian R Edlin; Patricia S Latham; Maria C Villacres; Ruth M Greenblatt; Marion G Peters
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

4.  Lysophosphatidylethanolamine Affects Lipid Accumulation and Metabolism in a Human Liver-Derived Cell Line.

Authors:  Yusuke Yamamoto; Toshihiro Sakurai; Zhen Chen; Nao Inoue; Hitoshi Chiba; Shu-Ping Hui
Journal:  Nutrients       Date:  2022-01-28       Impact factor: 5.717

5.  Selected Cytokines Serve as Potential Biomarkers for Predicting Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients With Normal to Mildly Elevated Aminotransferases.

Authors:  Yong-Qiong Deng; Hong Zhao; An-Lin Ma; Ji-Yuan Zhou; Shi-Bin Xie; Xu-Qing Zhang; Da-Zhi Zhang; Qing Xie; Guo Zhang; Jia Shang; Jun Cheng; Wei-Feng Zhao; Zhi-Qiang Zou; Ming-Xiang Zhang; Gui-Qiang Wang
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.